Spectrum Pharmaceuticals Performance
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Spectrum Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Spectrum Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Spectrum Pharmaceuticals is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Spectrum |
Spectrum Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest (100.00) in Spectrum Pharmaceuticals on November 16, 2025 and sell it today you would earn a total of 100.00 from holding Spectrum Pharmaceuticals or generate -100.0% return on investment over 90 days. Spectrum Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Spectrum, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Spectrum Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Spectrum Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Spectrum Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Spectrum Pharmaceuticals is not yet fully synchronised with the market data | |
| Spectrum Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Spectrum Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 10.11 M. Net Loss for the year was (75.4 M) with profit before overhead, payroll, taxes, and interest of 8.32 M. | |
| Spectrum Pharmaceuticals currently holds about 67.96 M in cash with (96.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37. |
Spectrum Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Spectrum Stock often depends not only on the future outlook of the current and potential Spectrum Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Spectrum Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 183.2 M | |
| Cash And Short Term Investments | 75.1 M |
Spectrum Pharmaceuticals Fundamentals Growth
Spectrum Stock prices reflect investors' perceptions of the future prospects and financial health of Spectrum Pharmaceuticals, and Spectrum Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Spectrum Stock performance.
| Return On Equity | -1.65 | |||
| Return On Asset | -0.38 | |||
| Profit Margin | (2.52) % | |||
| Operating Margin | (2.47) % | |||
| Current Valuation | 185.27 M | |||
| Shares Outstanding | 205.25 M | |||
| Price To Earning | (19.44) X | |||
| Price To Book | 2.40 X | |||
| Revenue | 10.11 M | |||
| EBITDA | (77.06 M) | |||
| Cash And Equivalents | 67.96 M | |||
| Cash Per Share | 0.37 X | |||
| Total Debt | 29.43 M | |||
| Debt To Equity | 0.06 % | |||
| Book Value Per Share | 0.13 X | |||
| Cash Flow From Operations | (96.99 M) | |||
| Earnings Per Share | (0.36) X | |||
| Total Asset | 103.34 M | |||
| Retained Earnings | (1.12 B) | |||
| Current Asset | 2.57 M | |||
| Current Liabilities | 2.52 M | |||
Things to note about Spectrum Pharmaceuticals performance evaluation
Checking the ongoing alerts about Spectrum Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Spectrum Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Spectrum Pharmaceuticals is not yet fully synchronised with the market data | |
| Spectrum Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Spectrum Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 10.11 M. Net Loss for the year was (75.4 M) with profit before overhead, payroll, taxes, and interest of 8.32 M. | |
| Spectrum Pharmaceuticals currently holds about 67.96 M in cash with (96.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37. |
- Analyzing Spectrum Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Spectrum Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Spectrum Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Spectrum Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Spectrum Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Spectrum Pharmaceuticals' stock. These opinions can provide insight into Spectrum Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Spectrum Stock
If you are still planning to invest in Spectrum Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spectrum Pharmaceuticals' history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |